Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street

269
56
Favorite

Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street

The Fly2022-10-28

Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a "bottom in sight" for the shares with PCs...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

269

Report

Comment（56）

vic78
·2022-10-30
👍👍
Reply
1
Report
Bull1973
·2022-10-29
Ok
Reply
Like
Report
AdrianTan
·2022-10-29
nice
Reply
Like
Report
Cvt
·2022-10-29
Good
Reply
7
Report
Fold Replies
- Ag1718:
  👍🏻🍭
  2022-10-29
  Reply
  Report
robot1234
·2022-10-29
Big Tech falters on dreary earnings and forecasts for Q4— Meta has worst week ever, Amazon tumbles 13%. Alphabet, Amazon, Meta and Microsoft combined lost over $350 billion in market cap this week. Forecasts were particularly gloomy for Meta and Amazon, as the economic slowdown punishes the former high flyers. In advertising, Amazon saw its business accelerate, while Facebook and Google are struggling. Other than Apple, it was a brutal earnings week for Big Tech. Third-quarter results this week came against the backdrop of soaring inflation, rising interest rates and a looming recession. Apple bucked the trend after beating expectations for revenue and profit. The stock on Friday had its best day in over two years. On the opposite end of the spectrum was Meta, which has seen its stock
Reply
15
Report
Fold Replies
- Tqt213:
  Okay
  2022-10-29
  Reply
  Report
- Gladys8jk:
  Ok
  2022-10-29
  Reply
  Report
- 大王木瓜:
  [Great]
  2022-10-29
  Reply
  Report
View more 2 comments
KCtan1688
·2022-10-29
Like
Reply
4
Report
Fold Replies
- Joyus:
  K
  2022-10-29
  Reply
  Report
- KCtan1688:
  Like
  2022-10-29
  Reply
  Report
Doris11
·2022-10-29
Like
Reply
2
Report
Will101
·2022-10-29
Ok
Reply
1
Report
Will101
·2022-10-29
Ok
Reply
4
Report
Fold Replies
- Will101:
  Ok
  2022-10-29
  Reply
  Report
Khoo18
·2022-10-29
K
Reply
5
Report
Fold Replies
- Doris11:
  ok
  2022-10-29
  Reply
  Report
wine18
·2022-10-29
Ok
Reply
9
Report
LIMKT
·2022-10-29
Ok
Reply
5
Report
JQ62
·2022-10-29
Like please
Reply
8
Report
Fold Replies
- ApacheFire:
  Yes
  2022-10-29
  Reply
  Report
- Khoo18:
  k
  2022-10-29
  Reply
  Report
MdmPhua
·2022-10-29
Okok
Reply
6
Report
Fold Replies
- MdmPhua:
  okk
  2022-10-29
  Reply
  Report
Bunifa Latif
·2022-10-29
Yes
Reply
3
Report
Fold Replies
- Bunifa Latif:
  K
  2022-10-29
  Reply
  Report
YJ Lee
·2022-10-29
Ok
Reply
4
Report
Fold Replies
- JQ62:
  ok
  2022-10-29
  Reply
  Report
Seah CL
·2022-10-29
K
Reply
4
Report
Fold Replies
- Seah CL:
  k
  2022-10-29
  Reply
  Report
phantom74
·2022-10-29
oike
Reply
2
Report
ML808
·2022-10-29
Great
Reply
4
Report
Fold Replies
- ML808:
  yes
  2022-10-29
  Reply
  Report
andrew123
·2022-10-29
Like
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1124585892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-10-28 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124585892","market":"us","top_or_hot":-1,"title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","media":"The Fly","content":"<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Source Link</a>\n\n</div>\n","source":"lsy1649979459173","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRTX","symbol_name":"Mirati Therapeutics Inc.","start_time":0,"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","article_id":"1124585892","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","pubTimestamp":1666965905,"sourceInfo":{"source_id":"lsy1649979459173","name":"The Fly"},"weMediaInfo":null,"summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","collect":0,"end_time":0,"defaultTopTitle":"thefly.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"MRTX":"Mirati Therapeutics Inc.","CAT":"卡特彼勒","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","AMPY":"Amplify Energy Corp.","GILD":"吉利德科学","LHX":"哈里斯公司","WU":"西联汇款","INTC":"英特尔","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","UBSFY":"UbiSoft Entertainment Inc.","TCNNF":"Trulieve Cannabis Corporation","FSLR":"第一太阳能","GERN":"杰龙"},"translate_title":"英特尔升级，元平台降级：华尔街的热门电话","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPY":0.9,"CAT":0.9,"CCB":0.9,"FSLR":0.9,"GERN":0.9,"GILD":0.9,"GTBIF":0.9,"INTC":0.9,"LHX":0.9,"META":0.9,"MRTX":0.9,"TCNNF":0.9,"TNL":0.9,"UBSFY":0.9,"WU":0.9},"content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9982982242,"gmtCreate":1667085630686,"gmtModify":1676537857138,"author":{"id":"3584874174562489","authorId":"3584874174562489","name":"vic78","avatar":"https://static.tigerbbs.com/d4dc3bd30cec435b0345175f72eeb4dc","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":0,"idStr":"3584874174562489","authorIdStr":"3584874174562489"},"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9982982242","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986745596,"gmtCreate":1667026545115,"gmtModify":1676537851817,"author":{"id":"3584680402793671","authorId":"3584680402793671","name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584680402793671","authorIdStr":"3584680402793671"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986745596","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986575750,"gmtCreate":1667000449871,"gmtModify":1676537845963,"author":{"id":"3568507662870938","authorId":"3568507662870938","name":"AdrianTan","avatar":"https://static.tigerbbs.com/b06609749cdea7e2f50b9bc7231997dc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3568507662870938","authorIdStr":"3568507662870938"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986575750","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986575633,"gmtCreate":1667000403922,"gmtModify":1676537845948,"author":{"id":"3579235597126488","authorId":"3579235597126488","name":"Cvt","avatar":"https://static.tigerbbs.com/c8fda02901ec7a98b51fe8e84d016ab2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579235597126488","authorIdStr":"3579235597126488"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986575633","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104567274,"gmtCreate":1667037881884,"gmtModify":1667037885178,"authorId":3582350348015234,"author":{"id":3582350348015234,"idStr":"3582350348015234","authorId":3582350348015234,"name":"Ag1718","avatar":"https://community-static.tradeup.com/news/7b99db6dd9dd4eaa84bd8baf04aad0b9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986575633,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">👍🏻🍭</span>","text":"<span class=\"s1\">👍🏻🍭</span>","html":"<span class=\"s1\">👍🏻🍭</span>"}],"langContent":"EN"},{"id":9986572680,"gmtCreate":1667000321441,"gmtModify":1676537845922,"author":{"id":"3561596430587504","authorId":"3561596430587504","name":"robot1234","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1,"idStr":"3561596430587504","authorIdStr":"3561596430587504"},"htmlText":"Big Tech falters on dreary earnings and forecasts for Q4— Meta has worst week ever, Amazon tumbles 13%. Alphabet, Amazon, Meta and Microsoft combined lost over $350 billion in market cap this week. Forecasts were particularly gloomy for Meta and Amazon, as the economic slowdown punishes the former high flyers. In advertising, Amazon saw its business accelerate, while Facebook and Google are struggling. Other than Apple,&nbsp;it was a brutal earnings week for Big Tech. Third-quarter results this week came against the backdrop of soaring inflation, rising interest rates and a looming recession. Apple bucked the trend after beating expectations for revenue and profit. The stock on Friday had its best day in over two years. On the opposite end of the spectrum was Meta, which has seen its stock","listText":"Big Tech falters on dreary earnings and forecasts for Q4— Meta has worst week ever, Amazon tumbles 13%. Alphabet, Amazon, Meta and Microsoft combined lost over $350 billion in market cap this week. Forecasts were particularly gloomy for Meta and Amazon, as the economic slowdown punishes the former high flyers. In advertising, Amazon saw its business accelerate, while Facebook and Google are struggling. Other than Apple,&nbsp;it was a brutal earnings week for Big Tech. Third-quarter results this week came against the backdrop of soaring inflation, rising interest rates and a looming recession. Apple bucked the trend after beating expectations for revenue and profit. The stock on Friday had its best day in over two years. On the opposite end of the spectrum was Meta, which has seen its stock","text":"Big Tech falters on dreary earnings and forecasts for Q4— Meta has worst week ever, Amazon tumbles 13%. Alphabet, Amazon, Meta and Microsoft combined lost over $350 billion in market cap this week. Forecasts were particularly gloomy for Meta and Amazon, as the economic slowdown punishes the former high flyers. In advertising, Amazon saw its business accelerate, while Facebook and Google are struggling. Other than Apple, it was a brutal earnings week for Big Tech. Third-quarter results this week came against the backdrop of soaring inflation, rising interest rates and a looming recession. Apple bucked the trend after beating expectations for revenue and profit. The stock on Friday had its best day in over two years. On the opposite end of the spectrum was Meta, which has seen its stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":15,"commentSize":12,"repostSize":0,"link":"https://ttm.financial/post/9986572680","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104559012,"gmtCreate":1667000544855,"gmtModify":1667000548133,"authorId":3581721392237078,"author":{"id":3581721392237078,"idStr":"3581721392237078","authorId":3581721392237078,"name":"Tqt213","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986572680,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Okay</span>","text":"<span class=\"s1\">Okay</span>","html":"<span class=\"s1\">Okay</span>"},{"id":104558981,"gmtCreate":1667000497833,"gmtModify":1667000501638,"authorId":4094787128284850,"author":{"id":4094787128284850,"idStr":"4094787128284850","authorId":4094787128284850,"name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986572680,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":104558978,"gmtCreate":1667000492132,"gmtModify":1667000495756,"authorId":4087112565401300,"author":{"id":4087112565401300,"idStr":"4087112565401300","authorId":4087112565401300,"name":"大王木瓜","avatar":"https://static.tigerbbs.com/0bdb060266f2f7b364f4ed52aa6519b6","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.15","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986572680,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">[Great]</span>","text":"<span class=\"s1\">[Great]</span>","html":"<span class=\"s1\">[Great]</span>"},{"id":104558974,"gmtCreate":1667000486122,"gmtModify":1667000489830,"authorId":3583013291377509,"author":{"id":3583013291377509,"idStr":"3583013291377509","authorId":3583013291377509,"name":"Jasonlim","avatar":"https://static.tigerbbs.com/267c1a2f725df0fb1a5215f427359d1e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986572680,"type":1,"supId":0,"prevId":0,"content":"<u>like</u>","text":"<u>like</u>","html":"<u>like</u>"},{"id":104558972,"gmtCreate":1667000481908,"gmtModify":1667000485434,"authorId":3560474608445356,"author":{"id":3560474608445356,"idStr":"3560474608445356","authorId":3560474608445356,"name":"Phantom121","avatar":"https://community-static.tradeup.com/news/e8c486af0a68427c4203e2d36d27c057","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986572680,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9986556081,"gmtCreate":1666997911943,"gmtModify":1676537845327,"author":{"id":"3572830110372716","authorId":"3572830110372716","name":"KCtan1688","avatar":"https://static.tigerbbs.com/eb264e77c49fffb1d26a89a47dbc0250","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572830110372716","authorIdStr":"3572830110372716"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9986556081","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558920,"gmtCreate":1667000366091,"gmtModify":1667000369637,"authorId":3574397806525082,"author":{"id":3574397806525082,"idStr":"3574397806525082","authorId":3574397806525082,"name":"Joyus","avatar":"https://static.tigerbbs.com/be788755f764f5e5e5cb1d49eec190f0","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986556081,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">K</span>","text":"<span class=\"s1\">K</span>","html":"<span class=\"s1\">K</span>"},{"id":104558347,"gmtCreate":1666997925081,"gmtModify":1666997928588,"authorId":3572830110372716,"author":{"id":3572830110372716,"idStr":"3572830110372716","authorId":3572830110372716,"name":"KCtan1688","avatar":"https://static.tigerbbs.com/eb264e77c49fffb1d26a89a47dbc0250","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986556081,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Like</span>","text":"<span class=\"s1\">Like</span>","html":"<span class=\"s1\">Like</span>"}],"langContent":"EN"},{"id":9986558335,"gmtCreate":1666997663028,"gmtModify":1676537845296,"author":{"id":"3583011761877766","authorId":"3583011761877766","name":"Doris11","avatar":"https://static.tigerbbs.com/3358aeedff213df7d1787b8f5e7a99ec","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583011761877766","authorIdStr":"3583011761877766"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986558335","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986558041,"gmtCreate":1666997599484,"gmtModify":1676537845288,"author":{"id":"3585476489553693","authorId":"3585476489553693","name":"Will101","avatar":"https://static.tigerbbs.com/0642b9beaee6b15c17a213aafa7b9791","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3585476489553693","authorIdStr":"3585476489553693"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986558041","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986551747,"gmtCreate":1666997593689,"gmtModify":1676537845288,"author":{"id":"3585476489553693","authorId":"3585476489553693","name":"Will101","avatar":"https://static.tigerbbs.com/0642b9beaee6b15c17a213aafa7b9791","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3585476489553693","authorIdStr":"3585476489553693"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986551747","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558304,"gmtCreate":1666997605457,"gmtModify":1666997618094,"authorId":3585476489553693,"author":{"id":3585476489553693,"idStr":"3585476489553693","authorId":3585476489553693,"name":"Will101","avatar":"https://static.tigerbbs.com/0642b9beaee6b15c17a213aafa7b9791","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986551747,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9986553862,"gmtCreate":1666997308556,"gmtModify":1676537845249,"author":{"id":"3586514899418238","authorId":"3586514899418238","name":"Khoo18","avatar":"https://static.tigerbbs.com/a895cde27a6f60014dacbbc8853a5e1e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586514899418238","authorIdStr":"3586514899418238"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986553862","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558308,"gmtCreate":1666997677361,"gmtModify":1666997680833,"authorId":3583011761877766,"author":{"id":3583011761877766,"idStr":"3583011761877766","authorId":3583011761877766,"name":"Doris11","avatar":"https://static.tigerbbs.com/3358aeedff213df7d1787b8f5e7a99ec","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986553862,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9986559596,"gmtCreate":1666997092015,"gmtModify":1676537845226,"author":{"id":"4109947078502812","authorId":"4109947078502812","name":"wine18","avatar":"https://community-static.tradeup.com/news/59f4bc3d6a36fcfd6ba5c4b8e84f5bc6","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":3,"crmLevelSwitch":0,"idStr":"4109947078502812","authorIdStr":"4109947078502812"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986559596","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986550488,"gmtCreate":1666996900544,"gmtModify":1676537845203,"author":{"id":"3586040086982725","authorId":"3586040086982725","name":"LIMKT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3586040086982725","authorIdStr":"3586040086982725"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986550488","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986550370,"gmtCreate":1666996795390,"gmtModify":1676537845187,"author":{"id":"3582865570179528","authorId":"3582865570179528","name":"JQ62","avatar":"https://static.tigerbbs.com/da715325270bb26fbcbce63e45f86a81","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582865570179528","authorIdStr":"3582865570179528"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9986550370","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558313,"gmtCreate":1666997717795,"gmtModify":1666997720904,"authorId":3560730969024945,"author":{"id":3560730969024945,"idStr":"3560730969024945","authorId":3560730969024945,"name":"ApacheFire","avatar":"https://community-static.tradeup.com/news/dadb20729b4de235c5471810de88a90d","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.64%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986550370,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Yes</span>","text":"<span class=\"s1\">Yes</span>","html":"<span class=\"s1\">Yes</span>"},{"id":104558287,"gmtCreate":1666997300809,"gmtModify":1666997304276,"authorId":3586514899418238,"author":{"id":3586514899418238,"idStr":"3586514899418238","authorId":3586514899418238,"name":"Khoo18","avatar":"https://static.tigerbbs.com/a895cde27a6f60014dacbbc8853a5e1e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986550370,"type":1,"supId":0,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"}],"langContent":"EN"},{"id":9986524175,"gmtCreate":1666996496897,"gmtModify":1676537845112,"author":{"id":"3583814135262824","authorId":"3583814135262824","name":"MdmPhua","avatar":"https://static.itradeup.com/news/67971848be29673bfd9e494fe2e662e5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583814135262824","authorIdStr":"3583814135262824"},"htmlText":"Okok","listText":"Okok","text":"Okok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986524175","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558177,"gmtCreate":1666996502771,"gmtModify":1666996506153,"authorId":3583814135262824,"author":{"id":3583814135262824,"idStr":"3583814135262824","authorId":3583814135262824,"name":"MdmPhua","avatar":"https://static.itradeup.com/news/67971848be29673bfd9e494fe2e662e5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986524175,"type":1,"supId":0,"prevId":0,"content":"okk","text":"okk","html":"okk"}],"langContent":"EN"},{"id":9986526879,"gmtCreate":1666995948691,"gmtModify":1676537845035,"author":{"id":"4101144485256300","authorId":"4101144485256300","name":"Bunifa Latif","avatar":"https://static.tigerbbs.com/26345dcc52c7fb5e31b8214c4b0f3b11","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":8,"crmLevelSwitch":0,"idStr":"4101144485256300","authorIdStr":"4101144485256300"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986526879","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558059,"gmtCreate":1666995955125,"gmtModify":1666995958528,"authorId":4101144485256300,"author":{"id":4101144485256300,"idStr":"4101144485256300","authorId":4101144485256300,"name":"Bunifa Latif","avatar":"https://static.tigerbbs.com/26345dcc52c7fb5e31b8214c4b0f3b11","vip":1,"currentWearingBadge":{"badgeId":"f00de38e20574ad1abf55a15966547c8-1","templateUuid":"f00de38e20574ad1abf55a15966547c8","name":"Average winning trade","description":"Top 50%","bigImgUrl":"https://community-static.tradeup.com/news/f53cdecfbff6499d133bad354ae10ff1","smallImgUrl":"https://community-static.tradeup.com/news/2554f84686bbcccc035b93fe29308e43","grayImgUrl":"https://community-static.tradeup.com/news/84c66bc70ac1cf09f4e89b1d4ca9d017","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.16","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5200},"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986526879,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">K</span>","text":"<span class=\"s1\">K</span>","html":"<span class=\"s1\">K</span>"}],"langContent":"EN"},{"id":9986528965,"gmtCreate":1666995762557,"gmtModify":1676537845003,"author":{"id":"4108816210230400","authorId":"4108816210230400","name":"YJ Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4108816210230400","authorIdStr":"4108816210230400"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986528965","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558225,"gmtCreate":1666996805243,"gmtModify":1666996808690,"authorId":3582865570179528,"author":{"id":3582865570179528,"idStr":"3582865570179528","authorId":3582865570179528,"name":"JQ62","avatar":"https://static.tigerbbs.com/da715325270bb26fbcbce63e45f86a81","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986528965,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9986521688,"gmtCreate":1666995710645,"gmtModify":1676537844988,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4102135564535180","authorIdStr":"4102135564535180"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986521688","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558036,"gmtCreate":1666995728205,"gmtModify":1666995731593,"authorId":4102135564535180,"author":{"id":4102135564535180,"idStr":"4102135564535180","authorId":4102135564535180,"name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986521688,"type":1,"supId":0,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"}],"langContent":"EN"},{"id":9986523980,"gmtCreate":1666995595140,"gmtModify":1676537844949,"author":{"id":"3570342809089528","authorId":"3570342809089528","name":"phantom74","avatar":"https://static.tigerbbs.com/c87ef2af41b8696be86cceafb5b5723d","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":0,"idStr":"3570342809089528","authorIdStr":"3570342809089528"},"htmlText":"oike","listText":"oike","text":"oike","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986523980","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986529571,"gmtCreate":1666995516994,"gmtModify":1676537844942,"author":{"id":"3582359360248748","authorId":"3582359360248748","name":"ML808","avatar":"https://static.tigerbbs.com/f601c68849ffbac8b7679f40f1471368","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":4,"crmLevelSwitch":0,"idStr":"3582359360248748","authorIdStr":"3582359360248748"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986529571","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104558003,"gmtCreate":1666995523671,"gmtModify":1666995527000,"authorId":3582359360248748,"author":{"id":3582359360248748,"idStr":"3582359360248748","authorId":3582359360248748,"name":"ML808","avatar":"https://static.tigerbbs.com/f601c68849ffbac8b7679f40f1471368","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986529571,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"EN"},{"id":9986529287,"gmtCreate":1666995497849,"gmtModify":1676537844933,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://community-static.tradeup.com/news/f2a1eaba26272212d42018e60e78b422","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":0,"idStr":"3576260758860416","authorIdStr":"3576260758860416"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986529287","repostId":1124585892,"repostType":4,"repost":{"id":"1124585892","pubTimestamp":1666965905,"share":"https://ttm.financial/m/news/1124585892?lang=&edition=fundamental","pubTime":"2022-10-28 22:05","market":"us","language":"en","title":"Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1124585892","media":"The Fly","summary":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>Barclays analyst Blayne Curtis upgraded <b>Intel</b> (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a &#34;bottom in sight&#34; for the shares with PCs closer to a bottom and cost cuts &#34;an important sober step after two years of unrealistic optimism.&#34; Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company&#39;s Q3 earnings report that he thinks the company&#39;s Q4 outlook and qualitative 2023 view &#34;encapsulate most, if not all, the current challenges for the company.&#34;</li><li>Piper Sandler analyst Do Kim upgraded <b>Gilead Sciences</b> (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says &#34;multiple roadblocks have cleared&#34; for the company&#39;s HIV and oncology franchises, providing greater visibility on future revenue growth.</li><li>Roth Capital analyst John White upgraded <b>Amplify Energy</b> (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify&#39;s cash on hand and free cash flow.</li><li>Goldman Sachs analyst Eric Sheridan upgraded <b>Ubisoft</b> (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.</li><li>Wolfe Research analyst Steve Fleishman upgraded <b>First Solar</b> (FSLR) to Outperform from Peer Perform with a $170 price target. The company had &#34;another surge of bookings&#34; in Q3 at even higher rates, Fleishman tells investors in a research note.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Edward Jones analyst David Heger downgraded <b>Meta Platforms</b> (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.</li><li>Deutsche Bank analyst Nicole Deblase downgraded <b>Caterpillar</b> (CAT) to Hold from Buy with a price target of $221, up from $196. &#34;There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,&#34; Deblase tells investors in a research note.</li><li>Raymond James analyst Brian Gesuale downgraded <b>L3Harris Technologies</b> (LHX) to Market Perform from Outperform without a price target. The stock&#39;s year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm&#39;s coverage space, Gesuale tells investors in a research note.</li><li>Credit Suisse analyst Benjamin Chaiken downgraded <b>Travel + Leisure</b> (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a &#34;quality&#34; company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.</li><li>UBS analyst Rayna Kumar downgraded <b>Western Union</b> (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a &#34;lackluster&#34; outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Wedbush analyst Robert Driscoll initiated coverage of <b>Geron</b> (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 &#34;in a large commercial market.&#34;</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Green Thumb Industries</b> (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.</li><li>BTIG analyst Jonathan DeCourcey assumed coverage of <b>Trulieve Cannabis</b> (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida&#39;s hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.</li><li>B. Riley analyst Kalpit Patel initiated coverage of <b>Mirati Therapeutics</b> (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen&#39;s (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.</li><li>Raymond James analyst David Feaster assumed coverage of <b>Coastal Financial Corporation</b> (CCB) with a Strong Buy rating and $57 price target. Coastal&#39;s Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Upgrades, Meta Platforms Downgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLR":"第一太阳能","TCNNF":"Trulieve Cannabis Corporation","UBSFY":"UbiSoft Entertainment Inc.","CAT":"卡特彼勒","GERN":"杰龙","LHX":"哈里斯公司","INTC":"英特尔","META":"Meta Platforms, Inc.","GTBIF":"Green Thumb Industries Inc.","WU":"西联汇款","GILD":"吉利德科学","CCB":"Coastal Financial Corp","TNL":"Travel Plus Leisure Co.","MRTX":"Mirati Therapeutics Inc.","AMPY":"Amplify Energy Corp."},"source_url":"https://thefly.com/landingPageNews.php?id=3605198&headline=META;CAT;LHX;TNL;GERN;AMPY;UBSFY;GILD;FSLR;INTC;WU;GTBIF;TCNNF;MRTX;CCB-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124585892","content_text":"Top 5 Upgrades:Barclays analyst Blayne Curtis upgraded Intel (INTC) to Equal Weight from Underweight with an unchanged price target of $30. The analyst sees a \"bottom in sight\" for the shares with PCs closer to a bottom and cost cuts \"an important sober step after two years of unrealistic optimism.\" Summit Insights analyst KinNgai Chan also upgraded Intel to Buy from Hold, telling investors after the company's Q3 earnings report that he thinks the company's Q4 outlook and qualitative 2023 view \"encapsulate most, if not all, the current challenges for the company.\"Piper Sandler analyst Do Kim upgraded Gilead Sciences (GILD) to Overweight from Neutral with a price target of $96, up from $79. The analyst says \"multiple roadblocks have cleared\" for the company's HIV and oncology franchises, providing greater visibility on future revenue growth.Roth Capital analyst John White upgraded Amplify Energy (AMPY) to Buy from Neutral with a $12 price target. White believes the litigation/lawsuits surrounding the Southern California Pipeline Incident have reached a satisfactory stage, the analyst tells investors in a research note. He believes that the criminal fines not covered by insurance will be easily met with Amplify's cash on hand and free cash flow.Goldman Sachs analyst Eric Sheridan upgraded Ubisoft (UBSFY) to Neutral from Sell with a price target of EUR 37, down from EUR 41. The analyst sees a more balanced risk/reward at current share levels.Wolfe Research analyst Steve Fleishman upgraded First Solar (FSLR) to Outperform from Peer Perform with a $170 price target. The company had \"another surge of bookings\" in Q3 at even higher rates, Fleishman tells investors in a research note.Top 5 Downgrades:Edward Jones analyst David Heger downgraded Meta Platforms (META) to Hold from Buy following the Q3 earnings report. While Meta is executing relatively well in the difficult macroeconomic environment and continues to steadily grow users across its platforms, Heger is concerned about how long the growing metaverse investment will take to deliver a sufficient return, the analyst tells investors in a research note.Deutsche Bank analyst Nicole Deblase downgraded Caterpillar (CAT) to Hold from Buy with a price target of $221, up from $196. \"There is simply not enough upside potential left vs. the current stock price to maintain a Buy rating,\" Deblase tells investors in a research note.Raymond James analyst Brian Gesuale downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. The stock's year to date outperformance, coupled with what he views as a downward bias to 2023 models and tense risk/reward debate on the 2023 guidance, no longer supports outperformance despite L3Harris remaining one of the higher quality defense names in the firm's coverage space, Gesuale tells investors in a research note.Credit Suisse analyst Benjamin Chaiken downgraded Travel + Leisure (TNL) to Underperform from Outperform with a price target of $31, down from $77. While Chaiken feels Travel + Leisure is a \"quality\" company, he thinks they will underperform peers due to its plans to move up the FICO spectrum, which should cause tour flow to come in lower than expected, the analyst tells investors in a research note.UBS analyst Rayna Kumar downgraded Western Union (WU) to Sell from Neutral with a $12 price target, reflecting 14% downside. The provided a \"lackluster\" outlook for a 2%-4% adjusted revenue decline in 2023 and a potential recession provides incremental risk given that management indicated its 2023 forecast does not include deterioration from current macro trends, Kumar tells investors in a research note.Top 5 Initiations:Wedbush analyst Robert Driscoll initiated coverage of Geron (GERN) with an Outperform rating and $5 price target. The company is developing telomerase inhibitor imetelstat for the treatment of a number of hematological diseases, including lower-risk myelodysplatic syndrome and myelofibrosis, Driscoll tells investors in a research note. The analyst anticipates positive top-line data from the ongoing Phase 3 study in LRMDS in early 2023, allowing for approval and initial launch in the first half of 2024 \"in a large commercial market.\"BTIG analyst Jonathan DeCourcey assumed coverage of Green Thumb Industries (GTBIF) with a Buy rating and C$28 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst cites the company having posted its 8th consecutive quarter of profitable earnings results, adding that he is confident that positive results will continue through his forecast period and beyond even in the face of macro headwinds.BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis (TCNNF) with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches.B. Riley analyst Kalpit Patel initiated coverage of Mirati Therapeutics (MRTX) with a Neutral rating and $72 price target. Despite a belief that Mirati is likely to gain accelerated approval for adagrasib in second-line metastatic non-small cell lung cancer by the December FDA action date date, a recent disappointment in the field, Amgen's (AMGN) weak data from its confirmatory trial in a similar setting, may limit commercial uptake relative to Street expectations, Patel tells investors in a research note.Raymond James analyst David Feaster assumed coverage of Coastal Financial Corporation (CCB) with a Strong Buy rating and $57 price target. Coastal's Q3 results exceeded Street forecasts, and its growth outlook remains robust as it continues to add new partners, where it maintains a solid pipeline of new potential partners, Feaster tells investors in a research note.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":269,"commentSize":56,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}